Taiwan FDA registration 931dbae787fd826b335ec0db0aedbeaa
Prinmosyot Type 2 fully automated glycoglobin analysis reagent
TW: 普林莫斯優特2型全自動化醣化血色素分析試劑
Taiwan·Risk Class 2·TRINITY BIOTECH PRIMUS CORPORATION DBA TRINITY BIOTECH·Registered Feb 23, 2006 – Feb 23, 2021CancelledRegistration details
- Analysis ID
- 931dbae787fd826b335ec0db0aedbeaa
- Customs Code
- DHA00601604801
Company information
- Manufacturer Country
- United States
- Authorized Representative
- PROGRESSIVE GROUP INC.
Product details
- Intended Use
- The Primmos ULTRA2 fully automated glycoglobin analysis system is a high-pressure liquid chromatography method to quantify glycohemoglobin in normal or diabetic patients in vitro diagnostic tests, which can be used with whole blood or diluted samples.
- Product Type (Level 1)
- B Hematology, pathology, and genetics
- Product Type (Level 2)
- B.7470 Analysis of glycosylated hemoglobin
- Import Information
- import
Dates and status
- Registration Date
- Feb 23, 2006
- Expiry Date
- Feb 23, 2021
- Cancellation Date
- Sep 19, 2023
Cancellation information
- Status
- Logged out
- Reason
- 自行鍵入
About this record
Access comprehensive regulatory information for Prinmosyot Type 2 fully automated glycoglobin analysis reagent in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 931dbae787fd826b335ec0db0aedbeaa and manufactured by TRINITY BIOTECH PRIMUS CORPORATION DBA TRINITY BIOTECH. The authorized representative in Taiwan is PROGRESSIVE GROUP INC..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices